40 citations
,
December 2019 in “Neurobiology of Stress” This review focuses on neuroactive steroids' influence on GABA-ergic signaling and discusses challenges in developing them for various therapeutic uses, citing recent excitement from FDA approval of allopregnanolone for postpartum depression but reporting no new results.
18 citations
,
September 2021 in “Journal of Neuroendocrinology” This review discusses how neurosteroids acting on GABAA receptors may influence behavior and explores the potential for developing selective modulators for treating psychiatric disorders, but reports no new clinical results.
June 2023 in “International journal of biology, pharmacy and allied sciences” This article discusses challenges primary care physicians face in diagnosing and treating depression, noting that up to one-third of antidepressant prescriptions involve non-indicated use; it also introduces FDA-approved treatments, esketamine nasal spray, and brexanolone IV injection.
19 citations
,
July 2023 in “Neuroscience & Biobehavioral Reviews” This review explores the role of neurosteroids in affective disorders, highlighting existing research on their impact on mood and discussing emerging evidence that endogenous neurosteroids may influence baseline emotional states.